| Elotuzumab, Selinexor, and Dexamethasone for Relapsed Refractory Multiple Myeloma (NCT05170789) | Tulane University School of Medicine | 2022-04-27 |
| A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma. (NCT05228470) | Pfizer | 2021-12-21 |
| Anti-BCMA Chimeric Antigen Receptor T Cells for Relapsed or Refractory Multiple Myeloma (NCT05577000) | Thomas Martin, MD | 2021-10-18 |
| A Trial for Relapsed Multiple Myeloma Patients (Isatuximab-dexamethasone) (NCT04965155) | EMN Trial Office S.r.l. Impresa Sociale | 2021-03-21 |
| A Study of ION251 Administered to Patients With Relapsed/Refractory Multiple Myeloma (NCT04398485) | Ionis Pharmaceuticals, Inc. | 2021-01-20 |
| Study of Melflufen (Melphalan Flufenamide) in Combination With Daratumumab in Relapsed-Refractory Multiple Myeloma (NCT04649060) | Oncopeptides AB | 2020-12-21 |
| A Study Evaluating The Safety And Pharmacokinetics Of Escalating Doses Of RO7297089 In Patients With Relapsed Or Refractory Multiple Myeloma (NCT04434469) | Genentech, Inc. | 2020-07-08 |
| Nivolumab, Ixazomib, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Myeloma (NCT04119336) | Andrew Yee, MD | 2020-02-14 |
| First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed or Refractory Multiple Myeloma (MM) (NCT04083534) | Regeneron Pharmaceuticals | 2019-09-26 |
| Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma. (NCT03158688) | Amgen | 2017-06-13 |
| UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep (NCT02722668) | Masonic Cancer Center, University of Minnesota | 2017-05-15 |
| Antiminor Histocompatibility Complex (MiHA) T Cells for Patients With Relapsed Hematologic Malignancies Following Matched HSCT (Guided Lymphocyte Immunopeptide Derived Expansion) (NCT03091933) | Ciusss de L'Est de l'Île de Montréal | 2017-02-06 |
| Non-interventional Study on Salvage Auto in Relapsed Myeloma (NCT02439476) | Association for Training, Education, and Research in Hematology, Immunology, and Transplantation | 2016-08-08 |
| ATRA, Celecoxib, and Itraconazole as Maintenance (NCT02401295) | University of Iowa | 2015-05-01 |
| Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Multiple Myeloma and Renal Disease (NCT01949532) | Amgen | 2014-01-01 |
| A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma (NCT01564537) | Takeda | 2012-08-01 |
| Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia (NCT01118689) | Millennium Pharmaceuticals, Inc. | 2010-11-01 |
| Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma (NCT01080391) | Amgen | 2010-07-14 |
| Vaccination With Peptides From Anti-apoptotic Proteins in Relapsed Multiple Myeloma (NCT01272466) | Herlev Hospital | 2010-02-01 |
| Phase 1b Multicenter Study of Carfilzomib With Lenalidomide and Dexamethasone in Relapsed Multiple Myeloma (NCT00603447) | Amgen | 2008-05-01 |
| Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma (NCT00153933) | Dana-Farber Cancer Institute | 2004-08-01 |
| A Phase 2 Study With Panzem in Patients With Relapsed or Plateau Phase Multiple Myeloma (NCT00592579) | CASI pharmaceuticals, Inc. | 2001-03-01 |